Is LDL-C passed its prime? The emerging role of Non-HDL, LDL-P, and ApoB in CHD risk assessment

被引：17
|
作者：
Davidson, Michael H. [1 ]
机构：
[1] Univ Chicago, Pritzker Sch Med, Chicago, IL 60654 USA
来源：
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2008年 / 28卷 / 09期
关键词：
D O I：
10.1161/ATVBAHA.108.172718
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1582 / 1583
页数：2
相关论文
共 50 条
  • [41] Real-world data, theoretical application of guidelines, cost, and access: how dowe optimize non-statin therapy for LDL-C/non-HDL-C/ApoB?
    Ballantyne, Christie M.
    Virani, Salim S.
    EUROPEAN HEART JOURNAL, 2020, 41 (40) : 3910 - 3912
  • [42] COMBINATION EZETIMIBE/SIMVASTATIN plus EXTENDED-RELEASE NIACIN THERAPY IMPROVES ATTAINMENT OF RECOMMENDED LDL-C, NON-HDL-C AND APOB LEVELS IN HYPERLIPIDEMIC PATIENTS
    Fazio, S.
    Guyton, J. R.
    Lin, J.
    Tomassini, J. E.
    Shah, A.
    Tershakovec, A. M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 20 - 20
  • [43] MORE AGGRESSIVE LDL-C AND NON-HDL-C TARGETS MUST BE ACHIEVED IN PATIENTS RECEIVING LIPID-LOWERING THERAPY TO NORMALIZE APOB-CONTAINING LIPOPROTEINS
    Betteridge, J.
    Guyton, J. R.
    Farnier, M.
    Leiter, L. A.
    Lin, J.
    Shah, A.
    Johnson-Levonas, A. O.
    Brudi, P.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 163 - 164
  • [44] Utility of ApoB target over LDL-C and non-HDL-C targets: insights from the national health and nutrition examination survey (NHANES) 2011-2012
    Quispe, R.
    Elshazly, M. B.
    Michos, E. D.
    Banach, M.
    Toth, P. P.
    Jones, S. R.
    Martin, S. S.
    EUROPEAN HEART JOURNAL, 2016, 37 : 403 - 403
  • [45] Enhanced attainment of optional recommended levels of LDL-C, apolipoprotein B, non-HDL and hsCRP in type 2 diabetes patients treated with ezetimibe/simvastatin compared to atorvastatin
    Weinstock, Ruth S.
    Goldberg, Ronald B.
    Guyton, John R.
    Mazzone, Theodore
    Polis, Adam
    Tomassini, Joanne E.
    Desrosiers, Elizabeth
    Tershakovec, Andrew M.
    CIRCULATION, 2006, 114 (18) : 796 - 797
  • [46] The Clinical Impact of TC/HDL-C Discordance With LDL-C and Non-HDL-C: 20 Year Follow-up of the Atherosclerosis Risk in Communities (ARIC) Study
    Quispe, Renato
    Elshazly, Mohamed B.
    Zhao, Di
    Toth, Peter P.
    Sniderman, Allan D.
    Puri, Rishi
    Virani, Salim S.
    Martin, Seth S.
    Jones, Steven R.
    Michos, Erin D.
    CIRCULATION, 2017, 135
  • [47] Serum apoB level is superior to non-HDL-C and LDL-C in the severity prediction assessed by Gensini Score among un-treated patients undergoing coronary angiography
    Zhang, Y.
    Li, S.
    Guo, Y. -L.
    Zhu, C. -G.
    Wu, N. -Q.
    Liu, G.
    Dong, Q.
    Li, J. J.
    EUROPEAN HEART JOURNAL, 2015, 36 : 282 - 282
  • [48] Importance of LDL-C/HDL-C as a Predictor of CHD in Non-Obese Patients With Type 2 Diabetes (T2DM): A Case-Control Study
    Fumisawa, Yasushi
    Yamauchi, Keishi
    Funase, Yoshiko
    Yamashita, Koh
    Aizawa, Toru
    DIABETES, 2012, 61 : A558 - A558
  • [49] ATTAINMENT OF SINGLE/DUAL TREATMENT LEVELS FOR LDL-C AND NON-HDL-C, APOB, OR HS-CRP IN PATIENTS WITH METABOLIC SYNDROME (MS): EZETIMIBE(E)/SIMVASTATIN(S) VS ATORVASTATIN(A)
    Ballantyne, C.
    Grundy, S.
    Hsueh, W.
    Parving, H.
    Robinson, J.
    Rosen, J.
    Lin, J.
    Lowe, R.
    Shah, A.
    Tomassini, J.
    Tershakovec, A.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [50] Role of Lipid Profile and Its Relative Ratios (Cholesterol/HDL-C, Triglyceride/HDL-C, LDL-C/HDL-C, WBC/HDL-C, and FBG/HDL-C) on Admission Predicts In-Hospital Mortality COVID-19
    Mohammadshahi, Jafar
    Ghobadi, Hassan
    Matinfar, Golchin
    Boskabady, Mohammad Hossein
    Aslani, Mohammad Reza
    JOURNAL OF LIPIDS, 2023, 2023
12345